Highlights Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Market Closed - Hong Kong S.E. Other stock markets 01:39:05 07/06/2024 pm IST			5-day change	1st Jan Change
6.3 ^HKD	-2.48%		-15.32%	-82.40%

03/06	Sirnaomics Medical, Finance Chiefs Step Down	MT
20/05	Sirnaomics' Strategy Chief Steps Down	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ	16/04	CI
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05/12	CI
Sirnaomics Ltd. Presents Positive Clinical Data of STP705 for Focal Fat Reduction	01/11	CI
Sirnaomics Buys US Unit's Shares for $1 Million	05/23/05	MT
Sirnaomics Narrows H1 Loss	31/23/31	MT
Sirnaomics Ltd. Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors	31/23/31	CI
Sirnaomics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
Sirnaomics Ltd. commences an Equity Buyback Plan for 8,854,483 shares, representing 10% of its issued share capital, under the authorization approved on June 28, 2023.	28/23/28	CI
Sirnaomics Ltd.'s Equity Buyback announced on July 12, 2022 has expired.	28/23/28	CI
Sirnaomics Advances STP705 for Squamous Cellcarcinoma in Situ into Late-Stage Clinical development	19/23/19	CI
Sirnaomics Ltd. Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty	05/23/05	CI
Sirnaomics Ltd. Doses the First Participant in Phase I Clinical Study of Galnac-Based Rnai Therapeutic STP122G for Anticoagulant Treatment	01/23/01	CI
Sirnaomics Ltd. to Receive Subsidy for Subsidy HKSTP Clinical Translational Catalyst Plan	17/23/17	CI
Sirnaomics Ltd. Launches Phase I Clinical Trial for Galnac Factor Xi Program	12/23/12	CI
Mobvista Swings to Profit in 2022	30/23/30	MT
Sirnaomics's 2022 Attributable Loss Narrows; Shares Down 3%	28/23/28	MT
Tranche Update on Sirnaomics Ltd.'s Equity Buyback Plan announced on July 12, 2022.	28/23/28	CI
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Sirnaomics Ltd. Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers	01/23/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Highlights

Filters